Hemoglobinuria, Paroxysmal - 24 Studies Found Recruiting : ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2016-10-25 : Biological: ALXN1210 Active, not recruiting : A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Nocturnal Hemoglobinuria PNH : 2015-11-11 : Biological: Study Drug- ALXN1210 Active, not recruiting : An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria : Paroxysmal Nocturnal Hemoglobinuria (PNH) : 2015-11-02 : Biological: Study Drug - ALXN1210 Recruiting : Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) : Paroxysmal Nocturnal Haemoglobinuria (PNH) : 2015-09-10 : Drug: Coversin Patients enrolled in this protocol will initially be treated with an ablating dose of Cov <<< Previous